The 43rd Annual J.P. Morgan Healthcare Conference commenced on January 13, 2025, in San Francisco, drawing approximately 8,000 industry leaders and professionals. The event is a pivotal platform for healthcare companies to showcase clinical milestones and explore potential merger and acquisition (M&A) opportunities. High-level executives from pharmaceutical giants like Johnson & Johnson and Pfizer, along with tech companies such as Nvidia, are in attendance. The conference is also notable for its tight security measures, heightened in response to the recent killing of UnitedHealthcare's CEO Brian Thompson. Amidst the conference, Corvus Pharmaceuticals announced new data from Cohort 2 of its Phase 1 clinical trial for soquelitinib, a drug being developed for atopic dermatitis. The data showed that 57% of patients achieved an EASI75 score with a 200mg once-daily dose, compared to 25% with a 100mg twice-daily dose, and no patients on placebo achieved this endpoint. Corvus Pharmaceuticals plans to present these findings at the conference on January 15, 2025.